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Abstract
Background: Gaucher disease (GD) is caused by mutations in the GBA1 gene which encodes lysosomal
β-glucocerebrosidase (GCase). In GD, partial or complete loss of GCase activity causes the accumulation of the
glycolipids glucosylceramide (GlcCer) and glucosylsphingosine in the lysosomes of macrophages.
In this manuscript, we investigated the effects of glycolipids accumulation on lysosomal and mitochondrial
function, inflammasome activation and efferocytosis capacity in a THP-1 macrophage model of Gaucher disease.
In addition, the beneficial effects of coenzyme Q10 (CoQ) supplementation on cellular alterations were evaluated.
Chemically-induced Gaucher macrophages were developed by differentiateing THP-1 monocytes to macrophages
by treatment with phorbol 12-myristate 13-acetate (PMA) and then inhibiting intracellular GCase with conduritol
B-epoxide (CBE), a specific irreversible inhibitor of GCase activity, and supplementing the medium with exogenous
GlcCer. This cell model accumulated up to 16-fold more GlcCer compared with control THP-1 cells.
Results: Chemically-induced Gaucher macrophages showed impaired autophagy flux associated with mitochondrial
dysfunction and increased oxidative stress, inflammasome activation and impaired efferocytosis. All abnormalities were
partially restored by supplementation with CoQ.
Conclusion: These data suggest that targeting mitochondria function and oxidative stress by CoQ can ameliorate the
pathological phenotype of Gaucher cells. Chemically-induced Gaucher macrophages provide cellular models that can
be used to investigate disease pathogenesis and explore new therapeutics for GD.
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Background
In LSDs, mutations in lysosomal hydrolases or trans-
porters result in the accumulation of specific macromol-
ecules, leading to progressive reduction in the capacity
of the lysosome for normal degradation processes, which
in turn leads to secondary changes such as impairment
in autophagic flux, mitochondrial dysfunction and in-
flammation [1]. Gaucher disease (GD), the LSD with the
highest prevalence, is caused by mutations in the GBA1
gene that results in defective and insufficient activity of
the enzyme β-glucocerebrosidase (GCase). Decreased
catalytic activity and/or instability of GCase leads to ac-
cumulation of glucosylceramide (GlcCer) and glucosyl-
sphingosine in the lysosomes of macrophages. Three
clinical forms (phenotypes) of the disease are commonly
recognized (Types 1, 2 and 3) of which by far the most
severe are those affecting the brain (Types 2 and 3).
Current treatments for GD include enzyme replacement
therapy with recombinant GCase and substrate-
reduction therapy which decreases the biosynthesis of
glucosylceramides and thereby reduces their accumula-
tion [2]. Many studies have implicated mitochondrial
* Correspondence: jasanalc@upo.es; http://www.upo.es/CABD/
1Centro Andaluz de Biología del Desarrollo (CABD), Consejo Superior de
Investigaciones Científicas, Universidad Pablo de Olavide, Carretera de Utrera
Km 1, Sevilla 41013, Spain
2Centro de Investigación Biomédica en Red: Enfermedades Raras, Instituto de
Salud Carlos III, Madrid 28029, Spain
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
de la Mata et al. Orphanet Journal of Rare Diseases  (2017) 12:23 
DOI 10.1186/s13023-017-0574-8
dysfunction in the pathogenesis of lysosomal diseases in
general and in GD in particular [3, 4]. The most pro-
nounced effect occurs in macrophages that participate in
ingesting blood cells and apoptotic lymphocytes. Thus,
the primary cell type affected in GD is the lipid laden
macrophage known as Gaucher cell. As macrophages
normally degrade large amounts of cellular membrane
lipids by phagocytosis, when GCase is absent or im-
paired, glycosphingolipids accumulate within the macro-
phage lysosome and the engorged cells in turn are
deposited in the liver, spleen, and lung, causing organ
enlargement and progressive dysfunction. GCase is dis-
tinguished from other O-glycosyl hydrolases by an acidic
pH optimum and a preference for glycolipids. Little is
known about the mechanisms by which GlcCer accumu-
lation leads to disease phenotype, particularly for those
in which severe neuropathology occurs. Specifically, it is
not known if altered macrophage function is responsible
for all of the pathological manifestations in all affected
tissues, or whether secondary biochemical changes
caused directly by GlcCer accumulation in the specific
tissues also play a role in the pathological process.
Therefore, determining how GlcCer accumulation per-
turbs the function of lysosomes and other organelles can
be important in elucidating the cascade of events that
give rise to the pathological consequences in GD.
In order to mimic the pathological phenotype of the
disease, an in vitro cellular model of Gaucher disease
was developed by treating the THP-1, a human mono-
cytic cell line differentiated into macrophage, with a spe-
cific inhibitor of GCase, conduritol beta epoxide (CBE)
[5] and the concomitant supplementation with exogen-
ous GlcCer (chemically-induced Gaucher THP-1 macro-
phages). Autophagy flux, mitochondrial dysfunction,
inflammasome activation and efferocitosis capacity were
examined in chemically-induced Gaucher THP-1 macro-
phages. In addition, as mitochondrial dysfunction and/or
impaired mitochondria elimination may be associated
with alterations of lysosome-dependent processes, treat-
ment with coenzyme Q10 (CoQ), an antioxidant and
mitochondrial energizer, was evaluated for the improve-
ment of cellular pathological alterations.
Methods
Reagents
Monoclonal Anti-Actin and Anti-NLRP3 antibodies were
obtained from Sigma-Aldrich (St. Louis, MO). Mitosox
Red, Mitotracker Red CMXRos, CMH2-DCFDA, 10-
N-nonyl acridine orange (NAO), LysoSensor Green
DND-189, tetramethylrhodamine methyl ester (TMRM),
CellTracker™ Green and Hoechst 33342 were from Invi-
trogen/Molecular Probes (Eugene, OR). Anti-GCase was
obtained from Abcam. Anti-cytochrome c antibody was
obtained from BD Biosciences Pharmingen (San Jose, CA)
and anti-GAPDH (Glyceraldehyde 3-phosphate de-
hydrogenase) monoclonal antibody (clone 6 C5) was
from Calbiochem-Merck Chemicals Ltd. (Nottingham,
UK). CBE, Anti-MAP LC3 (N-20), anti-LAMP-1 were
obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). Protease inhibitors were from Boehringer Mannheim
(Indianapolis, IN). Anti-IL-1β were obtained (Bioss, Inc).
Anti-Caspase 1 was obtained from (Cell Signaling
Tecnology, CST). The anti-GlcCer rabbit anti-serum
was purchased from Glycobiotech GmbH (Kükels,
Germany). Glucocerebrosides from Gaucher’s spleen
(GlcCer) was obtained from Matreya LCC (Pleasant Gap,
PA, USA). The Immun Star HRP substrate kit was from
Bio-Rad Laboratories Inc. (Hercules, CA, USA). All other
chemicals were purchased from Sigma-Aldrich.
Chemically-induced Gaucher macrophages
THP-1 cells (human monocytic cell line) were cultured in
RPMI medium supplemented with penicillin, strepto-
mycin, and 10% fetal bovine serum at 37 °C in a humidi-
fied 5% CO2 atmosphere and were first differentiated into
macrophages by phorbol 12-myristate 13-acetate (PMA;
Sigma-Aldrich) incubation at a final concentration of
100 ng/mL for 3 d and it was followed by 1 d in PMA-free
medium before treatments. Then, the Gaucher disease
phenotype was induced by chemical inhibition of acid β-
glucosidase with 2,5 mM CBE [5]. To exacerbate Gaucher
phenotype, the culture medium of THP-1 macrophages
was supplemented with exogenous GlcCer (200 μM).
Immunofluorescence microscopy
Immunofluorescence microscopy was performed using
standard methods as previously described [6]. Cover
slips were analyzed using a fluorescence microscope
(Leica DMRE, Leica Microsystems GmbH, Wetzlar,
Germany). Deconvolution studies and 3-dimensional
projections were performed using a DeltaVision system
(Applied Precision, Issaquah, WA) with an Olympus IX-
71microscope.
Measurement of mitochondrial reactive oxygen species
(ROS) production
Mitochondrial ROS generation was assessed using the
mitochondrial superoxide indicator MitoSOX Red, accord-
ing to the manufacturer’s instructions. ROS levels were
expressed relative to mitochondrial mass (ROS signal/
NAO signal) determined by flow cytometry. Cells were
stained with 10 μM NAO for 10 min at 37 °C in the dark.
Measurement of intracellular H2O2 content
H2O2 levels were measured using non fluorescent
CMH2-DCFDA (5-[and-6]-chloromethyl-2′,7′-dichloro-
dihydrofluoresceindiacetate, acetyl ester), which diffuses
across membranes and is oxidized to fluorescent
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dichlorofluorescein (DCF). Cultured cells were incubated
with CMH2-DCFDA diluted in medium at 5 μM for
30 min at 37 °C. After that, cells were analyzed by flow
cytometry.
Determination of mitochondrial membrane potential (ΔΨm)
ΔΨm was measured by staining with 20 nM TMRM or
100 nM Mitotracker Red CMXRos (30 min incubation).
Cells were subsequently analyzed by fluorescence mi-
croscopy and flow cytometry.
Immunoblotting analysis
Western blotting was performed using a standard proto-
col [7] and the Immun Star HRP detection kit (Bio-Rad
Laboratories Inc., Hercules, CA, USA).
Lysosome acidification
Lysosome acidification was measured by staining with
5 μM LysoSensor Green DND-189. LysoSensor was added
to cells in growth medium and incubated at 37 °C for
30 min before imaging and flow cytometry analysis. Lyso-
some acidification was also measured by 10 μg/ml acridine
orange staining (15 min incubation at 37 °C). Typically,
10–15 fluorescence microscopy images were collected
from 3 separate experiments and the red/green ratio of
discrete puncta (n = 200) were calculated using Image J.
Phagocytosis assay
Apoptosis was induced by treatment with 10 μM CPT
for 48 h treatment in CellTracker-labelled H460 cells ad-
hered to glass coverslips. Apoptosis was assessed by
fluorescence microscopy observing nuclei fragmentation
by Hoechst staining, cytochrome c release, and caspase
3 activation. Then, apoptotic cells were co-incubated
with control or chemically-induced Gaucher macro-
phages (150,000 cells/well). After 8 h of co-incubation at
37 °C, cells were fixed in 3.8% paraformaldehyde. The
number of control and chemically-induced Gaucher
macrophages interacting and engulfing cell fragments
was calculated in ten random fields in triplicate by fluor-
escence microscopy.
IL-1β levels
Samples from culture media from control and
chemically-induced Gaucher macrophages were col-
lected and stored at −80 °C until the assay. IL-1β levels
in culture media were determined in triplicates by com-
mercial ELISA kits (Human IL-1β CytoSetTM, Invitro-
gen, Camarillo, CA, USA).
Statistical analysis
All results are expressed as mean ± SD of 3 independent
experiments. The measurements were statistically ana-
lyzed using the Student’s t test for comparing 2 groups
and analysis of variance for more than 2 groups. The
level of significance was set at p < 0.05.
Results
Establishing a chemically-induced Gaucher macrophage
model
First, we examined whether chemically-induced Gaucher
THP-1 macrophages reproduce the pathological pheno-
type of this disease. As shown in Fig. 1a and b, GlcCer
accumulated in macrophages treated with CBE for 72 h.
This accumulation was significantly increased by ex-
ogenous 200 μM GlcCer supplementation (Fig. 1a and
b). GlcCer accumulation mainly colocalized with lyso-
somes which were labeled with LAMP-1 (Fig. 1a and
b). Hematoxylin/eosin staining of chemically-induced
Gaucher THP-1 macrophages also showed cells with
dilated vesicles presumably representing GlcCer accu-
mulation in lysosomes (Fig. 1c). These alterations were
particularly evident in cells treated with CBE and supple-
mented with GlcCer.
As GlcCer accumulation was significantly higher in
THP-1 cells treated with CBE and supplemented with
GlcCer we decided to work with this model in successive
experiments. Appropriate controls showing that patho-
physiological alterations are also more pronounced with
the combined treatment are provided in (Additional
files 1: Figures S1–S8).
CoQ treatment partially ameliorates GlcCer accumulation
in chemically-induced Gaucher THP-1 macrophages
As mitochondrial dysfunction has been associated with
alterations of lysosome-dependent processes, treatment
with CoQ, an antioxidant and mitochondrial energizer,
was evaluated for improving glycolipids accumulation in
cells treat with CBE and supplemented with ClcCer.
Supplementation with CoQ (25 μM) of chemically-
induced Gaucher THP-1 macrophages partially reduced
GlcCer accumulation and the number of GlcCer/LAMP-
1 puncta (Fig. 2a and b). Furthermore, in concordance
with this, there was a drastically reduction of dilated ves-
icles in hematoxylin/eosin stainings (Fig. 2c).
Autophagic flux is impaired in chemically-induced
Gaucher THP-1 macrophage model
As GlcCer accumulation in lysosomes may interfere with
lysosomal function and impair lysosomal fusion with
autophagosomes, we next examined autophagosome mat-
uration. To ascertain whether or not autophagic flux was
impaired in chemically-induced Gaucher THP-1 macro-
phages, we checked the levels of LC3-II in the presence of
bafilomycin A1 (Baf), a specific inhibitor of vacuolar H
+-ATPases and a blocker of autophagosome-lysosome fu-
sion (Fig. 3a and b). As expected, Baf treatment in control
THP-1 macrophages led to a significant increase in the
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amount of LC3-II suggesting that autophagic flux was
normal. However, basal LC3-II levels were increased in
chemically-induced Gaucher THP-1 macrophages, sug-
gesting autophagosome accumulation. Furthermore, Baf
treatment had no effect in LC3-II levels indicating that au-
tophagic flux was impaired (Fig. 3a and b). Supplementa-
tion with CoQ decreased the amount of basal levels of
LC3-II. Furthermore, LC3-II expression levels were
significantly increased after Baf treatment, suggesting im-
provement of autophagic flux (Fig. 3a and b).
Effect of CoQ supplementation on lysosomal pH and
mitochondrial membrane potential (ΔΨm) in chemically-
induced Gaucher THP-1 macrophages
Little is known about how GlcCer accumulation in lyso-
somes leads to cellular pathology. One critical question
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Fig. 1 Establishing a chemically-induced Gaucher macrophage model. a THP-1 macrophages were cultured in the presence or absence of CBE
(2,5 mM), GlcCer (200 μM) and CBE + GlcCer (2,5 mM + 200 μM) for 72 h. Cells were fixed and immunostained with anti-GlcCer and anti-LAMP-1
(Lysosomal marker) and examined by fluorescence microscopy. Lysosomal marker, LAMP-1, or GlcCer were visualized as red or green, respectively.
Colocalization of GlcCer signal with LAMP1 indicates GlcCer lysosomal accumulation b Quantification of GlcCer/LAMP-1 puncta in control and
macrophages incubated with CBE, GlcCer and CBE + GlcCer (n = 100 cells). Data represent the mean ± SD of three separate experiments. ap < 0.05
between CBE treatment and control cells. bp < 0.05 between GlcCer supplementation and control cells. cp < 0.05 between CBE + GlcCer combined
treatment and CBE or GlcCer treatment. c Representative images of Hematoxylin and eosin staining of chemically-induced Gaucher macrophages
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is whether GlcCer mediates all of its pathological effects
from within the lysosome, or whether some GlcCer
interact with biochemical and cellular pathways located
in other organelles as mitochondria.
As in Gaucher’s disease the accumulation of GlcCer
has been associated with an elevation in lysosomal pH
[8], we first determined whether GlcCer accumulation in
chemically-induced Gaucher THP-1 macrophages affects
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Fig. 2 Elevation of GlcCer levels and lysosomal markers colocalization in chemically-induced Gaucher macrophages. a Representative images of
GlcCer and lysosomal marker LAMP-1 in chemically-induced Gaucher macrophages. THP-1 macrophages were cultured in the presence or ab-
sence of CBE + GlcCer (2,5 mM+ 200 μM), or CBE + GlcCer + CoQ (2,5 mM + 200 μM+ 25 μM) for 72 h. Cells were fixed and immunostained with
anti-GlcCer and anti-LAMP-1 (Lysosomal marker) and examined by fluorescence microscopy. b Quantification Image analysis of GlcCer/LAMP-1
puncta in chemically-induced Gaucher macrophages incubated with or without CBE + GlcCer and CBE + GlcCer + CoQ (n = 100 cells). Data repre-
sent the mean ± SD of three separate experiments. cp < 0.05 between control and chemically-induced Gaucher macrophages. *p < 0.05 between
the presence and the absence of CoQ treatment. c Representative images of Hematoxylin and eosin staining of control, chemically-induced
Gaucher macrophages and chemically-induced Gaucher macrophages supplemented with CoQ
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lysosomal pH. Results indicated that the accumulation
of GlcCer impaired the acidification of these vesicles
(Fig. 4a). Flow cytometry analysis confirmed that
LysoSensor Green DND-189 fluorescence was decreased
in chemically-induced Gaucher THP-1 macrophages
(Fig. 4b). In addition, to assess mitochondrial dysfunction
in chemically-induced Gaucher THP-1 macrophages,
ΔΨm was evaluated by TMRM staining and fluorescence
microscopy visualization. TMRM fluorescence was de-
creased in chemically-induced Gaucher THP-1 macro-
phages, which reflects mitochondrial depolarization
(Fig. 4a). Mitochondrial depolarization was also confirmed
by flow cytometry analysis (Fig. 4c).
To elucidate whether CoQ had a beneficial effect on
lysosomal pH and ΔΨm impairment, chemically-induced
Gaucher macrophages were treated with 25 μM CoQ for
72 h. CoQ treatment resulted in a significant improve-
ment of both lysosomal pH and ΔΨm (Fig. 4a, b and c).
Lysosome acidification impairment in chemically-
induced Gaucher macrophages was also confirmed by
acridine orange staining. Chemically-induced Gaucher
macrophages showed a decrease in the red/green ratio
after acridine orange staining consistent with decreased
lysosomal acidity (Fig. 5a and b). Supplementation with
CoQ (25 μM) significantly increased the red/green ratio.
Effect of CoQ on reactive oxygen species (ROS)
production in chemically-induced Gaucher macrophages
It is well established that mitochondrial dysfunction is
associated with increased ROS production [9]. There-
fore, we examined mitochondrial ROS and H2O2
levels in chemically-induced Gaucher macrophages.
Mitochondrial superoxide production and H2O2 levels
were increased approximately by 2,5-fold and by 2-
fold respectively (Fig. 6a and b), suggesting increased
oxidative stress in chemically-induced Gaucher mac-
rophages. Supplementation with CoQ (25 μM), in-
duced a notably reduction in mitochondrial superoxide
and H2O2 levels in chemically-induced Gaucher mac-
rophages, but had no effect in control cultures (Fig. 6a
and b).
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Fig. 3 Impaired autophagic flux in chemically-induced Gaucher macrophages. a Autophagy flux. Determination of LC3-II expression levels in the
presence and absence of bafilomycin A1 in control and chemically-induced Gaucher macrophages. Control and chemically-induced
Gaucher macrophages were incubated with bafilomycin A1 (100 nM for 12 h). Total cellular extracts were analyzed by immunoblotting with antibodies
against LC3. Alpha-tubulin was used as a loading control. b Densitometry of Western blotting was performed using the ImageJ software. Data represent
the mean ± SD of three separate experiments. cp< 0.05 between control and chemically-induced Gaucher macrophages. *p< 0.05 between the presence
and the absence of CoQ. #p< 0.05 between the presence and the absence of bafilomycin A1
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Effect of CoQ on mitophagy in chemically-induced
Gaucher macrophages
Mitochondria can be degraded through mitophagy. To
determine whether the accumulated autophagosomes
in chemically-induced Gaucher macrophages contained
mitochondria, we performed immunofluorescence
double staining with antibodies against LC3 (autopha-
gosome marker) and cytochrome c (mitochondrial
marker) (Fig. 7a). LC3 staining was markedly increased
in chemically-induced Gaucher THP-1 macrophages re-
spect to control macrophages. In addition, LC3 signal
strongly colocalized with cytochrome c, suggesting that
mitochondria are engulfed by autophagosomes in
chemically-induced Gaucher THP-1 macrophages. Sup-
plementation with CoQ (25 μM) partially reduced the
number of LC3/cytochrome c puncta (Fig. 7b).
Effect of CoQ on inflammasome activation in chemically-
induced Gaucher macrophages
To determine the effect of GlcCer accumulation on
inflammasome activation, we evaluated NLRP3 expres-
sion levels and caspase-1 activation in chemically-
induced Gaucher macrophages. We found increased
NLRP3 expression levels and caspase-1 cleavage as well
DRAQ-5
T
H
P
-1
T
H
P
-1
+C
B
E
+G
lc
C
er
T
H
P
-1
+C
B
E
+G
lc
C
er
+C
o
Q
THP-1
+CBE
+GlcCer
+CoQ
0
50
100
150
200
THP-1
+CBE
+GlcCer
THP-1
+CoQ
THP-1
T
M
R
M
 
(F
lu
o
re
sc
en
ce
 m
ea
n
 In
te
n
si
ty
)
c
*
0
20
40
60
80
100
THP-1 THP-1
+CoQ
THP-1
+CBE
+GlcCer
THP-1
+CBE
+GlcCer
+CoQ
R
el
at
iv
e 
L
ys
o
se
n
so
r
fl
u
o
re
sc
en
ce
 in
te
n
si
ty
 (
%
vs
 T
H
 P
-1
)
c
*
TMRMLysosensora
cb
Fig. 4 Increase lysosomal pH is associated with decreased mitochondrial membrane potential (ΔΨm) in chemically-induced Gaucher macrophage.
a Representative images of control and chemically-induced Gaucher macrophages stained with LysoSensor Green DND-189 which accumulates
in acidic organelles and exhibits green fluorescence, and TMRM, a potentiometric fluorescent indicator that exhibits red fluorescence in mitochondria.
Effect of CoQ (25 μM) supplementation for 72 h on lysosomal pH and ΔΨm in chemically-induced Gaucher macrophages. b Determination of
lysosomal pH in both control and chemically-induced Gaucher macrophages by staining with LysoSensor Green DND-189 coupled to flow
cytometry analysis. Data represent the mean ± SD of three separate experiments. cp < 0.05 between control and chemically-induced Gaucher
macrophages. *p < 0.05 between the presence and the absence of CoQ treatment. c Determination ΔΨm was assessed by TMRM staining and
flow cytometry analysis. Data represent the mean ± SD of three separate experiments. cp < 0.05 between control and chemically-induced
Gaucher macrophages. *p < 0.05 between the presence and the absence of CoQ treatment
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as enhanced levels of intracellular and secreted IL-1β
compared to controls (Fig. 8a, b and c). CoQ treatment
resulted in a significant decrease in NLRP3 expression
levels, caspase-1 cleavage and intracellular and secreted
IL-1β levels (Fig. 8a, b and c).
Defective efferocytosis in chemically-induced Gaucher
macrophages
Given that apoptotic cells are rapidly phagocytosed by
macrophages, a process that represents a critical step in
tissue remodeling, immune responses, and the resolution
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Fig. 5 Lysosome acidification impairment in chemically-induced Gaucher macrophages. a Representative fluorescence images of THP-1 macrophages
cultured for 72 h with CBE +GlcCer (2,5 mM+ 200 μM) in the presence of CoQ (25 μM), and stained for 15 min with 10 μg/ml acridine orange. b Quanti-
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of inflammation, we evaluated the phagocytosis capacity
of chemically-induced Gaucher macrophages. In vitro
phagocytosis assays indicate a defective efferocytosis by
chemically-induced Gaucher macrophages with a signifi-
cant decrease of contacts and engulfment of apoptotic
cells. CoQ treatment resulted in a significant increase of
efferocytosis capacity in chemically-induced Gaucher
macrophages (Fig. 9a, b and c).
Discussion
Our study shows that GCase deficient activity and ac-
cumulation of GlcCer in a macrophage model of GD
can cause lysosomal and mitochondrial dysfunction
associated with inflammasome activation and impaired
efferocytosis. This study also showed that it is possible to
ameliorate the cellular pathological consequences of
GlcCer accumulation by targeting mitochondria and oxi-
dative stress with CoQ treatment.
In order to mimic the disease state, an in vitro model
of Gaucher disease was developed by treating THP-
1macrophagues with a specific irreversible inhibitor of
GCase, CBE, and exogenous GlcCer supplementation. In
previous works, GCase deficiency has been mimicked
treating he human neuroblastoma SHSY-5Y cell line
with CBE [10]. The treatment with CBE resulted in frag-
mentation of mitochondria, significant progressive
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Fig. 6 Increase ROS production in chemically-induced Gaucher macrophage. a Mitochondrial ROS levels in control and chemically-induced
Gaucher macrophages. Results are expressed as the ratio of MitoSOX signal to 10-N-nonyl acridine orange signal in the absence or presence of
CoQ (25 μ M) for 72 h. MitoSOX and 10-N-nonyl acridine orange signal were determined by flow cytometry analysis. Data represent the mean ±
SD of three separate experiments. cp < 0.05 between control and chemically-induced Gaucher macrophages. *p < 0.05 between the presence and
the absence of CoQ treatment. b H2O2 levels in control and chemically-induced Gaucher macrophages by CMH2-DCFDA staining coupled with
flow cytometry analysis. H2O2 levels in control and chemically-induced Gaucher macrophages cultured in the absence or presence of CoQ
(25 μ M) for 72 h. Data represent the mean ± SD of three separate experiments. cp < 0.05 between control and chemically-induced Gaucher
macrophages. *p < 0.05 between the presence and the absence of CoQ treatment. c Representative fluorescence images of MitoSox (red) and
GlcCer (green) staining
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decline in mitochondrial membrane potential, reduction
of ATP synthesis and an increase in ROS production.
Furthermore, an animal model and in vitro models for
Gaucher disease have been produced by injecting mice
or treating macrophages with CBE, causing intracellular
storage of endogenous GlcCer [11, 12]. However, in
addition to endogenously synthesized GlcCer, storage
material in Gaucher cells is also thought to originate
from the turnover of exogenously derived lipids in cell
membranes of phagocytosed red and white blood cells.
For this reason and in order to exacerbate the disease
phenotype, in addition to GCase inhibition, we supple-
mented the culture medium with exogenous GlcCer. In
our cell model, lipid storage would be expected to occur
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Fig. 7 Colocalization of autophagosome and mitochondria markers in chemically-induced Gaucher macrophages. a Mitochondria Image analysis
of LC3 and cytochrome c immunostaining in control and chemically-induced Gaucher macrophages. Control and chemically-induced Gaucher
macrophages were cultured in the presence or absence of CoQ (25 μM) for 72 h. Cells were fixed and immunostained with anti-LC3 (autophago-
some marker) and cytochrome c (mitochondrial marker) and examined by fluorescence microscopy. b Quantification of LC3/cytochrome c puncta
in control and chemically-induced Gaucher macrophages incubated with or without CoQ (n = 100 cells). Data represent the mean ± SD of three
separate experiments. cp < 0.05 between control and chemically-induced Gaucher macrophages. *p < 0.05 between the presence and the absence
of CoQ treatment
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much more rapidly and to more closely mimic the dis-
ease state. These GlcCer-laden Gaucher macrophages
have a characteristic morphology with extensive pres-
ence of lysosomal lipid deposits. Currently, many of the
available mouse models of Gaucher disease are not suit-
able for these studies because most knock-in mouse
models carrying human mutations in glucocerebrosidase
do not display an accurate disease phenotype or are le-
thal [13]. Thus, cell-based Gaucher disease models may
provide an alternative approach for evaluating the effi-
cacy of new therapeutic strategies.
In GD, accumulation of sphingolipids has been shown
to alter autophagy by reducing autophagosome clear-
ance, and so promoting their accumulation [14]. Indeed,
alteration of autophagic flux has been demonstrated in
GD cell models [3]. Furthermore, increased number of
autophagosomes has been observed in hypomorphic
prosaposin mice carrying the homozygous V394L Gba1
mutation that showed accumulation of GlcCer [15].
Degradation of engulfed material is primarily mediated
by lysosomal enzymes that function optimally within a
narrow range of acidic pH values. Elevation of lysosomal
pH in Gaucher cells interferes with the degradation
process and may contribute to the associated pathologies
[16]. Recently, there have been increased reports show-
ing that lysosomal pH may be regulated [17] and that
GlcCer accumulation may have an important role in its
dysregulation [8]. Our results showed that GlcCer accu-
mulation impaired lysosome acidification and as a result
may alter the activity of lysosomal hydrolases which may
result in secondary substrate accumulation [18]. The ac-
cumulation of primary and secondary substrates pro-
vokes a cascade of events that impacts not only the
endosomal–autophagic–lysosomal system, but also in
other organelles including mitochondria, the ER, Golgi,
peroxisomes, and overall the cell function [1].
Furthermore, our results confirm previous experi-
ments that showed that autophagic flux is reduced in
most LSDs [19]. This is evident from the combined ele-
vation of autophagic substrates and autophagosome-
associated LC3-II in chemically-induced Gaucher
macrophages.
Constitutive macroautophagy maintains mitochondrial
quality by selectively degrading dysfunctional mitochon-
dria via a process known as mitophagy [20]. Therefore,
reduced autophagic flux in LSDs may lead to the persist-
ence of dysfunctional mitochondria [21–25]. In addition
of impaired mitochondria quality control, some authors
have hypothesized that variations in GlcCer and cer-
amide might play an important role in the development
of mitochondrial dysfunction in GD [26]. Furthermore,
it has been reported that the sphingolipid ceramides
provoke oxidative stress by disrupting mitochondria and
inducing lethal mitophagy [27]. In agreement with these
results, we have previously reported that GlcCer is accu-
mulated mainly in the lysosomal and mitochondrial
compartments in fibroblasts derived from Gaucher pa-
tients and that both accumulation of GlcCer and
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Fig. 8 Inflammasome activation in chemically-induced Gaucher
macrophages. a Western blot analysis of NLRP3, caspase-1 and
IL-1β in control and chemically-induced Gaucher macrophages
treated with CoQ (25 μM) for 72 h. Cells were supplemented
with lipopolysaccharides (LPS) the last 24 h. Alpha-tubulin was
used as loading control. b Densitometric analysis of Western
blottings. Data represent the mean ± SD of three separate experiments.
cp < 0.05 between control and chemically-induced Gaucher macro-
phages. *p < 0.05 between the presence and the absence of CoQ treat-
ment. c IL-1β levels were determined by ELISA assay as described in
Material and Methods. Data represent the mean ± SD of three separate
experiments. cp < 0.05 between control and chemically-induced
Gaucher macrophages. *p < 0.05 between the presence and the
absence of CoQ treatment
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impairment of autophagic flux may induce mitochon-
drial dysfunction in Gaucher disease [3].
Dysfunctional mitochondria are involved in the patho-
genesis of several neurodegenerative diseases. The proper
elimination of damaged mitochondria is needed in post-
mitotic neurons because progressive accumulation of
damaged mitochondria might eventually lead to cell death.
Mitochondrial dysfunction with reduced respiratory chain
complex activities, increased ROS production and de-
creased potential in neurons and astrocytes has recently
been reported in a mouse model of type II neuronopathic
GD [28].
GlcCer accumulation within inflammatory cells as
macrophages may contribute to persistent and altered
inflammatory responses in GD. In GD patients, elevated
levels of some cytokines and chemokines have been re-
ported including IL-1β, interleukin-1 receptor antagon-
ist, IL-6, IL-8, IL-10, IL18, TNF-α, M-CSF, and
pulmonary and activation-regulated chemokine (PARC
or CCL-18) [29–32]. A similar finding was noted using
THP-1 cells differentiated into macrophages by retinoic
acid and treated with the GCase inhibitor CBE [33].
Normal human mesenchymal stromal cells treated with
CBE also showed an up-regulation of genes involved in
proteolysis, lipid homeostasis, and the inflammatory re-
sponse [34]. In this manuscript, we show that impaired
autophagic flux is associated with inflammasome activa-
tion and increased maturation of IL-1β in a chemically-
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induced Gaucher macrophage model. These findings
provide a link between impaired autophagy and in-
creased secretion of pro-inflammatory cytokines in
Gaucher cells. Consistent with our results, macrophages
derived from peripheral monocytes from patients with
type 1 Gaucher disease with genotype N370S/N370S
showed an increased secretion of interleukins IL-1β and
IL-6 [35]. Our findings are also supported by studies in
patients with type 1 GD [29], in mouse models of GD
[36] and in iPSC‐derived cells [37].
However the exact mechanism by which GlcCer accu-
mulation activates the NLRP3 inflammasome is not yet
understood. Several recent data have shown that autoph-
agy, and in particular mitophagy, are key links among
inflammasome, ROS production and mitochondrial dys-
function [38, 39] .
Macrophages are involved in many essential processes
including the removal of pathogens and dead cells
through phagocytosis [40]. This may contribute to the
accumulation of unphagocytosed debris from cells
undergoing apoptosis in the course of homeostatic tissue
remodeling and repair. Mutant GBA macrophages accu-
mulate undigested lysosomal material, which disrupts
endocytic recycling and impairs their migration and en-
gulfment of dying cells. This causes a buildup of unen-
gulfed cell debris.
Given that chemically-induced Gaucher macrophages
manifest their defective storage phenotype, we also evalu-
ated their phagocytosis capability. We found impaired
efferocytosis in chemically-induced Gaucher macrophages.
In agreement with our findings, impaired microbicidal
capacity of mononuclear phagocytes from patients with
type I Gaucher Disease has been previously reported [41].
Given that defects in energy metabolism and oxidative
stress have been demonstrated to play a role in the
pathogenesis of GD, we envisioned that the treatment
with coenzyme CoQ could also exert beneficial thera-
peutic effects. The fundamental role of CoQ in mito-
chondrial bioenergetics and its well-acknowledged
antioxidant properties constitute the basis for its clinical
applications, although some of its effects may be related
to a gene induction mechanism [42]. Interestingly for
the treatment of neuropathic GD, CoQ is also able to
cross the BBB [43].
The treatment with CoQ is currently considered as a
potential experimental drug for the treatment of neuro-
degenerative diseases in general [44] and lysosomal dis-
eases in particular [45]. Apart from mitochondria where
CoQ functions as an electron and proton donor in the
mitochondrial respiratory chain, high levels of CoQ have
been also reported in lysosomes. CoQ plays a key role in
the exchange of electrons in lysosomal membrane, which
contributes to protons’ translocation into the lumen and
to the acidification of intra-lysosomal medium, which is
essential for the proteolytic function of hydrolases respon-
sible–when deficient- of a wide range of inherited lyso-
somal diseases [46]. Consistent with these findings, the
treatment with CoQ improved mitochondrial/lysosomal
function, increased autophagic flux and reduced inflam-
masome activation as well as improved efferocytosis cap-
acity of chemically-induced Gaucher macrophages.
These results, however, should be interpreted with
caution since the positive effects of CoQ in vitro may
not have an equivalent beneficial effect when translated
to human clinical trials as it has been recently demon-
strated in two large trials in Parkinson and Huntington
diseases [47, 48].
Conclusion
Our results support the hypothesis that lysosomal dys-
function interferes with the clearance of damaged mito-
chondria and that the two critical pathways, lysosomal
and mitochondrial dysfunction converge in the patho-
genesis of GD. In addition, CoQ supplementation par-
tially corrected many of the cellular pathophysiological
alterations. Therefore, we proposed that boosting lyso-
somal function in conjunction with improvements of
mitochondrial function will have a protective effect on
GD. Studies in a suitable animal model may provide pre-
clinical data, which may support clinical trials with CoQ
given in human patients with GD.
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